247 related articles for article (PubMed ID: 18302198)
1. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
Bao BY; Chuang BF; Wang Q; Sartor O; Balk SP; Brown M; Kantoff PW; Lee GS
Prostate; 2008 Jun; 68(8):839-48. PubMed ID: 18302198
[TBL] [Abstract][Full Text] [Related]
2. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.
Chouinard S; Barbier O; Bélanger A
J Biol Chem; 2007 Nov; 282(46):33466-33474. PubMed ID: 17848572
[TBL] [Abstract][Full Text] [Related]
3. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
4. Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.
Zimmer BM; Howell ME; Wei Q; Ma L; Romsdahl T; Loughman EG; Markham JE; Seravalli J; Barycki JJ; Simpson MA
Horm Cancer; 2016 Aug; 7(4):260-71. PubMed ID: 27307252
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.
Hu DG; Mackenzie PI
Drug Metab Dispos; 2010 Dec; 38(12):2105-9. PubMed ID: 20736324
[TBL] [Abstract][Full Text] [Related]
6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
7. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
[TBL] [Abstract][Full Text] [Related]
8. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
He J; Lan X; Duan HL; Luo H; Zhou XD
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
10. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
Wijayakumara DD; Hu DG; Meech R; McKinnon RA; Mackenzie PI
J Pharmacol Exp Ther; 2015 Sep; 354(3):417-25. PubMed ID: 26163549
[TBL] [Abstract][Full Text] [Related]
12. Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia.
Zhan H; Zhang S; Li L; Chen Z; Cai Y; Huang J; Wu D; Huang B; Wu B; Liu X
J Steroid Biochem Mol Biol; 2022 Jul; 221():106117. PubMed ID: 35504423
[TBL] [Abstract][Full Text] [Related]
13. Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling.
Chouinard S; Yueh MF; Tukey RH; Giton F; Fiet J; Pelletier G; Barbier O; Bélanger A
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):247-53. PubMed ID: 18467088
[TBL] [Abstract][Full Text] [Related]
14. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
15. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.
Sun T; Wang Q; Balk S; Brown M; Lee GS; Kantoff P
Cancer Res; 2009 Apr; 69(8):3356-63. PubMed ID: 19351832
[TBL] [Abstract][Full Text] [Related]
16. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.
Lévesque E; Beaulieu M; Guillemette C; Hum DW; Bélanger A
Endocrinology; 1998 May; 139(5):2375-81. PubMed ID: 9564848
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
Margaillan G; Lévesque É; Guillemette C
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):85-93. PubMed ID: 26385605
[TBL] [Abstract][Full Text] [Related]
19. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.
Chang GT; Blok LJ; Steenbeek M; Veldscholte J; van Weerden WM; van Steenbrugge GJ; Brinkmann AO
Cancer Res; 1997 Sep; 57(18):4075-81. PubMed ID: 9307296
[TBL] [Abstract][Full Text] [Related]
20. Effect of fibroblastic growth factors (FGF) on steroid UDP-glucuronosyltransferase expression and activity in the LNCaP cell line.
Lévesque E; Beaulieu M; Guillemette C; Hum DW; Bélanger A
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):43-8. PubMed ID: 9569009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
